Lipoprotein (a) (Lp(a)), is a subclass of low density were found in hypertensives when compared to conlipoprotein (LDL) which contains a single additional trols, with weak correlations between Lp(a) and apolipoprotein, apo(a). Although Lp(a) was orig-LDL-cholesterol and triglycerides; there was no corinally described as a blood group antigen, 1 current relation, however, between Lp(a) and blood pressinterest in the lipoprotein relates to its association ure, and coagulation or fibrinolytic parameters. In a with vascular disease, for which it appears to be an recent study of out-patients attending a hypertenindependent risk factor.
2 Apo(a) has considerable sion clinic, we also found significant elevations in structural homology to plasminogen, although its Lp(a) levels in hypertensives compared to controls. 8 protease domain is enzymatically inactive: in vitro Median Lp(a) levels were particularly elevated studies however, suggest that apo(a) may interfere amongst black hypertensive patients, consistent with fibrinolysis. 3 In addition, Lp(a) could have both with previous observations of high Lp(a) levels in a thrombogenic potential, due to its apo(a) moiety, this ethnic group. 8 A report by Sechi et al 9 did not and an atherogenic potential due to the LDL find any differences in serum Lp(a) between hypermoiety. 4 tensives and normotensive controls, but serum Lp(a) In this issue of the Journal of Human Hypertenlevels were related to hypertensive target organ sion, we report a study by Catalano et al, 5 where damage, independent of the level of blood pressure. plasma Lp(a) concentrations were significantly There is, however, considerable evidence which higher in patients with essential hypertension when shows that multiple metabolic cardiovascular risk compared to age-and sex-matched control subjects.
factors, including dyslipidaemia, often co-exist with Median Lp(a) concentrations in their patients were, hypertension.
10
In addition, the relationship however, well within the conventional normal between hypertension and lipid abnormalities may range, and the proportion of hypertensive patients be causally related to insulin resistance, as facets of who actually had levels greater than 30 mg/dl, Reaven's syndrome. 11 Even though the number of which is a level often regarded as associated with components of Reaven's syndrome has broadened an increased risk of vascular disease, was the same since its original description, and that abnormalities as in control subjects. They conclude that essential in Lp(a) have not been 'officially'-linked to this synhypertensives have higher levels of Lp(a), albeit drome, it should be pointed out that there also within the normal range, thus contributing to their appears to be no relationship between insulin levels increased risk of vascular disease.
as a surrogate for insulin resistance, and Lp(a) The study by Catalano et al 5 contributes to relalevels.
12
tively limited studies on Lp(a) and hypertension. The first question concerning the findings of CataTheir review of the literature has highlighted conlano et al 5 is whether any confounding factors may trasting results, with many studies showing no sighave influenced their results. In particular, genetic, nificant differences in Lp(a) concentrations between rather than acquired, factors have the major influhypertensive patients and controls; nevertheless, ence on plasma Lp(a) concentrations. 13 Apo(a) is some exceptions do occur. 6, 7 In the study by Dondalso subject to a genetic polymorphism, with isoers et al, 7 for example, significant elevations in Lp(a) forms differing substantially in molecular weight due to alleles having different degrees of re-duplication of the Kringle IV coding domain, and the mol-distribution of apo(a) genotypes in a particular study Catalano et al 5 had mean plasma total cholesterol concentrations of 5.7 mmol/L, which would be difpopulation, often determined experimentally as a phenotype by apo(a) electrophoresis and immunoficult to describe as unduly high. There was also no significant correlations between Lp(a) and other blotting, would therefore have a significant influence upon average plasma Lp(a) concentrations in lipid parameters in their study. Nevertheless, the cross-sectional study by Sechi et al 9 did suggest a that particular population. Only one investigation appears to have reported both apo(a) phenotypes relationship between hypertensive target organ damage and Lp(a); perhaps further longitudinal studies and Lp(a) concentrations in hypertensives, 14 and this found no difference in either between patients exploring this relationship are needed. Finally, there is limited data on the prognostic and controls. Apo(a) phenotyping was not performed in the studies reporting a link between Lp(a) and predictive value of routine clinical measurements of Lp(a), even in hypertensive patients, and and hypertension, 5,7,8 and hence whether we can truly exclude a genetic effect on the outcome is there are also few therapeutic manoeuvres which can be reliably used to lower Lp(a), with no clear debatable. In the report by Sechi et al, 9 there was a significantly higher frequency of low molecular evidence of benefit. 4 Perhaps it may be more appropriate to measure the routine lipid profile of cholesweight apo(a) isoforms with increasing severity of hypertensive target organ damage, the latter being terol, HDL and triglycerides in hypertensive patients, since these, together with age, gender, associated with higher serum Lp(a) levels. The possibility that hypertensives in the studies blood pressure, diabetes mellitus and LVH, at least accurately predict the risk of subsequent cardioreporting a link between Lp(a) and hypertension 5, 7, 8 had greater target organ damage, compared to subvascular disease. Treatment to lower total cholesterol or LDL cholesterol could then be initiated, jects in 'negative' studies needs to be considered.
Assuming that there were no differences in apo(a) especially if the patient is at risk. Until further reliable data and therapeutic interventions are availphenotypes between patients and controls, one or more acquired factors could perhaps be involved in able, routine measurement of Lp(a) in hypertensives should perhaps be simply regarded as a research the elevations in Lp(a). However, there are relatively few acquired factors which are known to affect Lp(a) exercise, in attempting to relate the various pathophysiological mechanisms leading to the vascular levels, and even fewer which are plausible in this cohort. For example, insulin resistance, a common complications of hypertension. feature of hypertension, appears not to alter plasma Lp(a) levels. Proteinuria will increase plasma Lp Lp(a) levels. lesterolaemia, and hypertensives in the study by
